Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia - Blood Cancer Journal
Source : https://www.nature.com/articles/s41408-022-00760-z
A significant body of literature has been generated related to the detection of measurable residual disease (MRD) at the time of achieving complete remission (CR) in patients with hairy cell...
Conclusions: Here we provide a consensus report on the available data, the potential merits of MRD assessment in the front-line and relapse settings and recommendations on future role of MRD assessment in HCL.
The dual role of CD70 in B-cell lymphomagenesis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36471481/
Our findings suggest that CD70 can play a role in either tumour suppression or oncogenesis in DLBCL, likely via distinct immune evasion mechanisms, that is, impairing T cell priming or...
Conclusions: Our findings suggest that CD70 can play a role in either tumour suppression or oncogenesis in DLBCL, likely via distinct immune evasion mechanisms, that is, impairing T cell priming or inducing T cell exhaustion. Characterisation of specific dysfunction of CD70 in DLBCL may thus provide opportunities for the development of novel...
-
MRD Connect3yrKey Points • Source: Clinical and Translational Medicine • Conclusions: “Our findings suggest that CD70 can play a role in either tumour suppression or oncogenesis in DLBCL, likely via distinct immune evasion mechanisms, that Show More
Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: A real-life CLL campus study
Source : https://www.frontiersin.org/articles/10.3389/fonc.2022.1033413/full
One of the main issues in the treatment of patients with chronic lymphocytic leukemia (CLL) deals with the choice between continuous or fixed-duration therapy. Continuous ibrutinib (IB), the first-in-class BTK...
Conclusions: Although continuous IB provides better disease control in CLL, IGHV mutated patients and those achieving an undetectable MRD show a marked clinical and economic benefit from a fixed-duration obinutuzumab-based treatment.
Optimal approach to T-cell ALL - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36485168/
T-lineage acute lymphoblastic leukemia (T-ALL) is curable for most children and adolescent and young adult patients with contemporary frontline chemotherapy regimens. During the past decade, improved survival rates have resulted...
Relevance: In this article I review the current frontline chemotherapy regimens for adult patients with T-ALL, summarize the novel targeted and immune therapeutics currently in early-phase clinical trials, and outline how these therapies are helping to define an optimal approach for T-ALL.
Microfluidic isolation of aptamers with affinity towards multiple myeloma monoclonal immunoglobulins - Biomedical Microdevices
Source : https://link.springer.com/article/10.1007/s10544-022-00643-x
Multiple myeloma (MM) is a bone marrow cancer of resident plasma cells that affects 125,000 patients in the U.S. with about 30,000 new cases per year. Its signature is the...
Conclusions: We demonstrate that high-affinity DNA aptamers (KD